Close menu




Biotech

Photo credits: pixabay.com

Commented by Fabian Lorenz on September 12th, 2025 | 07:15 CEST

200% shares Steyr Motors and PanGenomic Health! When will cancer-fighter BioNTech explode?

  • Healthcare
  • healthtech
  • Automotive
  • Biotechnology

More than 200% price gains are not enough: Steyr Motors and PanGenomic Health continue to go full throttle. Despite its strong performance in recent weeks, PanGenomic still appears undervalued. With the use of artificial intelligence, the Canadians want to tap into the billion-dollar market for personalized alternative medicine and dietary supplements in North America. Their e-commerce platform has just gone live. Steyr Motors reports several successes in China, opening up a billion-dollar market for the Austrians. In contrast, BioNTech shares are not moving. Yet the Mainz-based company is increasingly becoming a real cancer fighter. Will the stock soon explode?

Read

Commented by Armin Schulz on September 12th, 2025 | 07:05 CEST

Investing in the future of medicine: A look at Novo Nordisk, NetraMark Holdings and Evotec

  • Biotechnology
  • Biotech
  • AI
  • Pharma

AI is completely transforming the pharmaceutical industry. Modern algorithms sift through vast amounts of data, identify promising therapeutic approaches, and advance drug development at record speed. This increase in efficiency is an absolute game changer. Not only does it save billions, but it also significantly increases success rates and catapults agile companies to the forefront. While cumbersome large corporations laboriously digitize their research departments, disruptive start-ups with innovative AI platforms are shaking up the market. It is precisely this dynamic that presents unique opportunities for investors, if they know how to decipher them. Today, we take a closer look at Danish pharmaceutical giant Novo Nordisk, AI specialist NetraMark Holdings, and German research service provider Evotec.

Read

Commented by Armin Schulz on September 11th, 2025 | 07:10 CEST

Forget weight loss injections! BioNxt Solutions is unsettling Big Pharma, but could become an important partner

  • Biotechnology
  • Biotech
  • Pharma

There is a catch with weight loss injections: they are injections. Studies show that adherence to treatment drops dramatically after one year. What if the blockbuster drug could simply be dissolved under the tongue? That is precisely what BioNxt Solutions is working on. With its patented dissolvable film technology, the Canadian-German biotech company not only aims to revolutionize obesity therapy but also make strides in multiple sclerosis treatment. The approach could transform entire markets.

Read

Commented by Fabian Lorenz on September 10th, 2025 | 07:20 CEST

Evotec downgraded! Out of Hensoldt? Into Pure Hydrogen?

  • Hydrogen
  • cleantech
  • Defense
  • Biotechnology

Out of Hensoldt and into Rheinmetall? That is what analysts are suggesting—at least indirectly. Valuation is becoming a headache. How do other experts view the share's performance? In contrast, an exciting buying opportunity seems to be developing at Pure Hydrogen. With their openness to technology, the Australian company is clearly striking the right chord with customers. Once again, they have managed to win over a client in the US – the world's largest commercial vehicle market. Heavy commercial vehicles with fuel cell drives are scheduled for delivery before the end of this year. The stock is unlikely to remain this cheap for long. At Evotec, on the other hand, the MDAX downgrade is weighing heavily, with the stock trading close to its multi-year low. Analysts see almost 100% upside potential, but investors are not responding.

Read

Commented by Armin Schulz on September 10th, 2025 | 07:05 CEST

Oncology boom: How Bayer, Vidac Pharma, and BioNTech could outperform with their full pipelines

  • Biotechnology
  • Biotech
  • Pharma
  • Oncology

The oncology industry is facing an unprecedented wave of growth: the global market is expected to double to over USD 866 billion by 2034. Driven by demographic factors, groundbreaking immunotherapies, and a record number of new drugs, investors are facing a historic window of opportunity. Those who invest in the right innovators with bulging pipelines and disruptive technologies can benefit from this mega-trend wave. This is precisely where the promising strategies of Bayer, Vidac Pharma, and BioNTech come in.

Read

Commented by André Will-Laudien on September 9th, 2025 | 10:05 CEST

The next wave is coming! NetraMark and BioNTech are on the winning track - Can Novo Nordisk and Eli Lilly follow suit?

  • Biotechnology
  • Biotech
  • Pharma

Artificial intelligence (AI) is transforming the development of new drugs by analyzing complex data at lightning speed and making clinical trials more efficient. AI technologies enable candidates to be selected more specifically for research projects and therapeutic successes to be predicted with greater precision. Companies such as NetraMark and BioNTech have already successfully used these tools, with the Mainz-based company currently even achieving breakthroughs in oncology. Meanwhile, Novo Nordisk and Eli Lilly, once stars of the obesity market, are now seen as "fallen angels". Will they manage to turn things around? Investors with foresight now have new opportunities in rapidly growing billion-dollar markets. A long-awaited interest rate cut in the US could be the spark the sector needs! Selection is now key!

Read

Commented by Fabian Lorenz on September 9th, 2025 | 07:20 CEST

Takeover candidate! Novo Nordisk and Eli Lilly eyeing BioNxt Solutions

  • Biotechnology
  • Biotech
  • Takeover
  • Innovations

A portfolio rocket for the coming weeks? The shares of BioNxt Solutions are certainly worth a closer look. There was no sign of a summer slump at this company - quite the opposite, as one major announcement followed another, and the newsflow continues into September. The Canadian-German life sciences company specializes in innovative drug delivery technologies. The latest bombshell: BioNxt aims to replace the Ozempic weight-loss injection with a tablet-like oral form of administration. This move opens the door to another billion-dollar market and positions the Company as a takeover candidate. Novo Nordisk, Eli Lilly, and others are engaged in fierce competition and are hungry for innovations – like those developed by BioNxt. The stock remains attractively priced.

Read

Commented by Stefan Feulner on September 8th, 2025 | 07:10 CEST

Opendoor, Almonty Industries, BioNTech – Great opportunities outside the tech bubble

  • Mining
  • Tungsten
  • Defense
  • Technology
  • Gold
  • Biotechnology
  • RealEstate

While the Nasdaq 100 continued to lose momentum last week, along with leading tech stocks, the crisis metal gold celebrated a new all-time high at USD 3,586 per ounce. The escalating geopolitical crises and the intensifying trade war between the US and China are likely to drive prices for critical raw materials in the long term. Western producers remain attractively valued.

Read

Commented by Nico Popp on September 4th, 2025 | 07:25 CEST

AI reaches medicine – Here is where it has the greatest impact: NetraMark, Siemens Healthineers, Intuitive Surgical

  • Biotechnology
  • Biotech
  • AI
  • healthtech

AI is revolutionizing more and more industries. A recent article in Handelsblatt highlights the enormous potential in medicine and names Siemens Healthineers and Intuitive Surgical as the beneficiaries. AI would significantly increase the often-lacking efficiency in industry. According to Handelsblatt, citing analysts from Fortune Business Insights, the market for AI in healthcare could grow by 44% annually to USD 504 billion by 2032. We show where the greatest leverage exists and which companies are still small enough to benefit disproportionately from developments in the coming years.

Read

Commented by Nico Popp on September 4th, 2025 | 07:05 CEST

What comes after the weight loss injection? How does BioNxt intend to outperform Eli Lilly and Novo Nordisk?

  • Biotechnology
  • Biotech
  • Pharma

The weight loss injection is all the rage. Not only are celebrities shedding significant pounds with it, but many people in our own circles are also losing weight effortlessly thanks to modern GLP-1 receptor agonists. Many patients report that they simply do not feel hungry anymore. This is already having an impact on the restaurant industry in the US – people are ordering more salads and splitting desserts. With Wegovy and similar drugs, one to two teaspoons of tiramisu is enough. But this billion-dollar market is far from reaching all patients. What groundbreaking developments in modern weight loss drugs are already in the pipeline, and how can investors benefit?

Read